Stonegate Pharmacy LP, Austin, TX

Is Stonegate Pharmacy LP registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Stonegate Pharmacy LP hold a Texas pharmacy license?

The Texas State Board of Pharmacy lists license 24369 for STONEGATE PHARMACY, AUSTIN, status Active, as of Nov 15, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 8228 for Stonegate Pharmacy, Austin, TX, status Active, as of Nov 15, 2026.

Has Stonegate Pharmacy LP had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Apr 24, 2019), 2 state referral letters (Apr 24, 2019 and Sep 21, 2020) and 2 FMD-145 letters (Apr 24, 2019 and Sep 21, 2020) for Stonegate Pharmacy LP. State board actions: the Texas State Board of Pharmacy file dated Nov 15, 2026 marks prior disciplinary orders on license 24369 (column DISP ACTN, value Y); the orders themselves are on the board’s license lookup and are not copied here. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Stonegate Pharmacy LP
Location
Austin, TX
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 21, 2020
FDA Data Dashboard inspections
3 inspections: 1 OAI, 2 VAI; 4 published Form 483s
Form 483 text on this page
2 Form 483s, 9 observations
State board records
License found: 24369, Active

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Stonegate Pharmacy LP, a 503A facility, with 6 dated actions.

Document
Sep 21, 2020FMD-145 letterFMD-145 Letter Issued 09/21/2020FDA copy (archived)
Sep 21, 2020State referral letterReferral Letter to the Texas State Board of Pharmacy Issued 09/21/2020FDA copy (archived)
Aug 9, 2019Form 483483 Issued 08/09/2019FDA copy (archived)
Apr 24, 2019Warning letter close-outWarning Letter Close Out Issued 04/24/2019Not linked by FDA
Apr 24, 2019FMD-145 letterFMD-145 Letter Issued 04/24/2019FDA copy (archived)
Apr 24, 2019State referral letterReferral Letter to the Texas State Board of Pharmacy Issued 04/24/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Stonegate Pharmacy LP, Austin, TX (FEI number 3012038236), matched to this page by exact name, city and state. It lists 3 inspections: 1 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Aug 9, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30120382361099307
Jun 11, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30120382361056181
Mar 2, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3012038236961047

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 9 numbered observations in all, across 2 inspections ending Jun 11, 2018 to Aug 9, 2019. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 30, 2019 to Aug 9, 2019: 5 observations

Firm on the cover
Stonegate Pharmacy LP, 2501 W William Cannon Dr Ste 203, Austin, TX 78745-5255
FEI number
3012038236
Establishment type on the cover
Producer of Sterile Drug Products
FDA district office on the cover
4040 North Central Expressway, Suite 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

Specifically,

A. On 07/30/2019, I witnessed your firm's pharmacy technician's failure to cover exposed skin around the forehead and eyes while producing sterile drug products in your ISO 5 laminar airflow hood, brand name <Redacted B4>, serial number <Redacted B4>, model <Redacted B4> Your pharmacy technician's eye and forehead areas entered the ISO 5 sterile environment while producing sterile injectable drug products. Your firm's pharmacy technician produced the following three sterile drug products on 07/30/2019~ Crorionic Gonadotropin 5,000 U/mL Solution, Lot #07292019:92@45, Quantity <Redacted B4>, Testosterone Cypionate (Grapeseed Oil) 40 mg/mL Oil Injection Solution, Lot #07302019:92@4, Quantity <Redacted B4> and Testosterone USP (Ethyl Oleate) 200 mg/mL Oil Injection Solution, Lot #07302019:67@1, Quantity <Redacted B4>

B. On 07/30/2019, I witnessed your firm's pharmacy technician's failure to utilize clean non-sterile booties throughout the day while performing sterile production tasks. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Specifically,

On 07/30/2019, I witnessed your firm's failure to secure the entry door to your <Redacted B4> area. Your firm utilized what appeared to be a stack of white napkins to prop up the door to your <Redacted B4> area while producing Methylcobalamine/Methionine/lnositol/Choline 1/25/50/50, Rapid Dissolve Tablets, Lot #06192019:74@15, Quantity <Redacted B4>. The door to your firm's negative pressure <Redacted B4> area has fallen twice and your firm has not performed any risk assessment after each occurrence. Your firm does not maintain any maintenance records for said door. According to your pharmacist-in-charge, your firm <Redacted B4> area is used primarily for the production of hormone containing drug products. Your firm does not follow an process assigned to mitigate drug product cross contamination. The <Redacted B4> area is adjacent to a drug product storage area and <Redacted B4> non-sterile <Redacted B4> hoods in the non-sterile laboratory.

Observation 3

Equipment was and Materials or supplies were not disinfected prior to entering the aseptic processing areas.

Specifically,

B. On 07/30/2019, I witnessed your firm's pharmacy technician's failure to disinfect blue vial stickers prior to entry into the ISO 5 sterile environment. These blue vial stickers were applied to all drug product vials produced in the laminar airflow hood. Sablue stickers entered the ISO 5 environment without being wiped/disinfected with <Redacted B4> sterile <Redacted B4> The blue stickers are staged directly above your laminar airflohood. Your firm's pharmacy technician produced the following three sterile drug products on 07/30/2019, Chorionic Gonadotropin 5,000 U/mL Solution, Lot #07292019:92@45, 04 Quantity <Redacted B4> Testosterone Cypionate (Gra)leseed Oil) 40 mg/mL Oil Injection Solution, Lot #07302019:92@4, Quantity <Redacted B4> and Testosterone USP ~thyl Oleate) 200 mg/mL Oil Injection Solution, Lot #07302019:67@1, Quantity <Redacted B4>

id

w

Observation 4

Specifically,

On 07/30/2019, I witnessed your firm's failure to properly store unsealed prefilters awaiting fl, installation into vour laminar airflow hood ISO 5 environment, <Redacted B4> serial <Redacted B4>, model <Redacted B4> Said unsealed prefilters were stored directly on the ground in your anteroom room and then moved to the non-sterile area of the laboratory, near a trash can.

Observation 5

Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

Specifically,

1. On 07/ 30/ 2019, I witnessed your firm's failure to maintain calibration records for your <Redacted B4>, brand name <Redacted B4> serial number <Redacted B4>, utilized to test your sterile injectable drug products. Your <Redacted B4> libration records date only back to June 27th, 2019. Your firm's calibration <Redacted B4> for your <Redacted B4>, do not specify expiration dating and only represent(b) (>calibration points 4 and <Redacted B4>

2. On 07/30/2019, I witnessed your firm's failure to utilize a calibratable thermometer in your freezer that is dedicated to drug product storage. This is where your firm stores sterile injectable solutions pending distribution. All of your freezer temperature records/logs are based on this non-calibratable <Redacted B4> brand thermometer. ...

Read the full 483 (PDF on fda.gov)

Inspection May 30, 2018 to Jun 11, 2018: 4 observations

Firm on the cover
Stonegate Pharmacy LP, 2501 W. Willia m Canno n D r. S te 203, Austin, TX 79745-5255
Establishment type on the cover
Producer of Sterile and Non -Sterile Drug Products
FDA district office on the cover
40 40 No rth Ce ntral Ex pressway, Su ite 30 0 D allas, TX 75 204 (
Matched to this page by
firm name, city and state on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Media fills were not performed that closely simulate aseptic production operations incorporating as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.

Media fills conducted by your aseptic technicians do not represent routine production nor they simulate worst ca se scenarios or mo st challenging conditions Fo r ex ample, yo ur firm pr oduced a ba tch of G

This is a repeat observation from the previous inspection conducted in 2016.

Observation 2

Personnel hand washing procedure was c onducted i n a w ay that may have cause the gowning apparel to b ecome contaminated.

On 6/5/2018, I observed the sterile technician remove her lab coat, cap and replace her shoe covers prior to entering rhe clean side of the IS07 anteroom where she proceeded to wash her hands before sterile gowning. During the hand washing procedure, I observed tap water from the sink splashing the front of her scrubs and splashing on the <Redacted B4> door next to her shoes which were covered with shoe covers. She proceeded <Redacted B4> don sterile garments such as a sterile mask, sterile gown, sterile gloves but did not change her shoe covers that may have been contaminated with microbiological organisms found in tap water that splashed on the floor during the hand washing procedure and entered the IS07 buffer room containing the ISOS laminar air flow hood.

splashing on the Qoor next to her shoes which were covered with shoe covers. ...

Read the full 483 (PDF on fda.gov)

Observation 3

a) Your firm <Redacted B4> sterilizes vials of Testosterone in <Redacted B4> and <Redacted B4>. The sterile technician stated that <Redacted B4>. However, your firm does not follow the manufacturer's insert which states that the <Redacted B4> is to be <Redacted B4>. Your firm's sterile technician stated that the <Redacted B4> processed in the <Redacted B4>. There is no assurance that the vials sterilized by <Redacted B4> to render the vials of Testosterone in <Redacted B4> sterile. Approximately <Redacted B4> prescriptions of Testosterone vials in <Redacted B4> have been distributed that were <Redacted B4> sterilized in the <Redacted B4> since 3/1/2018.____

b) Your firm < Re dacted B4> s terilizing Te stosterone. Testosteron e/Anastrozle and/ or Estradio l pelle ts i n the <Re dact ed B4>. However , you do not <Redacted B4> used to house the pellets. The <Redacted B4> are not processed or subjected to the same conditions a s t he pellets ther efore there is no as surance tha t the <Re dac ted B4> parameters utilized to steri lize the pellets are adequate. Approximately <Red ...

Read the full 483 (PDF on fda.gov)

Observation 4

Stock solutions used in the preparation of sterile finished drug products are not <Redacted B4> sterilized nor stored in sterile containers.

Your firm prepares <Redacted B4>, a stock solution that is used as a component in the production of Chorionic Gonadotropin Solution (HCG), an aseptically filled sterile injectable drug product of various strengths such as but not limited to 5,000IU/ml and 10,000IU/ml. The <Redacted B4> stock solution is not <Redacted B4> sterile and is not placed in sterile containers. The beyond use date for this stock solution is <Redacted B4>. The following lots of <Redacted B4> have been prepared without being <Redacted B4> sterilized nor stored in sterile containers lo limit or reduce bioburden Lo control potential proliferation of bacterial endotoxins and were used io the production of HCG in various strengths. Since 3/1/2018, approximately <Redacted B4> prescriptions have been <Redacted B4> fulfilled of various strengths of HCG of which the <Redacted B4> stock solution was used.

Linked 483s whose text is not shown

State board of pharmacy records

The Texas State Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatusPrior disciplinary orders (file flag)
24369Community Sterile CompoundingSTONEGATE PHARMACYAUSTINActiveYes

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 8228OSPStonegate PharmacyAustin, TXActive

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.